|
Name |
Dehydroaustinol
|
Molecular Formula | C25H28O8 | |
IUPAC Name* |
(1R,2S,5S,7S,8S,9R,12S,13S)-8-hydroxy-2,6',6',9,13-pentamethyl-6,16-dimethylidenespiro[10,14,17-trioxapentacyclo[7.6.1.17,12.01,12.02,7]heptadecane-5,5'-pyran]-2',11,15-trione
|
|
SMILES |
C[C@H]1[C@@]23C(=O)O[C@]4([C@@H]([C@]5(O2)C(=C)[C@]6(CC[C@]5([C@@]3(C4=C)C(=O)O1)C)C=CC(=O)OC6(C)C)O)C
|
|
InChI |
InChI=1S/C25H28O8/c1-12-21(7)16(27)24-13(2)22(9-8-15(26)31-19(22,4)5)11-10-20(24,6)23(12)17(28)30-14(3)25(23,33-24)18(29)32-21/h8-9,14,16,27H,1-2,10-11H2,3-7H3/t14-,16-,20-,21+,22+,23+,24+,25-/m0/s1
|
|
InChIKey |
IQBUQLYYAHHCGX-LRSNFHFMSA-N
|
|
Synonyms |
Dehydroaustinol; (1'R,2'S,3S,7'S,8'S,9'R,12'S,13'S)-8'-hydroxy-2,2,2',9',13'-pentamethyl-6',16'-bis(methylene)-6H-spiro[pyran-3,5'-[10,14,17]trioxapentacyclo[7.6.1.1(7,12).0(1,12).0(2,7)]heptadecane]-6,11',15'-trione; CHEBI:64421; Q27133275
|
|
CAS | NA | |
PubChem CID | 56955928 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 456.5 | ALogp: | 1.0 |
HBD: | 1 | HBA: | 8 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 108.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 33 | QED Weighted: | 0.337 |
Caco-2 Permeability: | -5.43 | MDCK Permeability: | 0.00004000 |
Pgp-inhibitor: | 0.022 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.072 | 20% Bioavailability (F20%): | 0.977 |
30% Bioavailability (F30%): | 0.966 |
Blood-Brain-Barrier Penetration (BBB): | 0.97 | Plasma Protein Binding (PPB): | 53.56% |
Volume Distribution (VD): | 1.052 | Fu: | 54.56% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.993 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.728 |
CYP2C9-inhibitor: | 0.017 | CYP2C9-substrate: | 0.006 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.019 |
CYP3A4-inhibitor: | 0.659 | CYP3A4-substrate: | 0.909 |
Clearance (CL): | 4.03 | Half-life (T1/2): | 0.114 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.96 |
Drug-inuced Liver Injury (DILI): | 0.933 | AMES Toxicity: | 0.988 |
Rat Oral Acute Toxicity: | 0.989 | Maximum Recommended Daily Dose: | 0.914 |
Skin Sensitization: | 0.924 | Carcinogencity: | 0.982 |
Eye Corrosion: | 0.189 | Eye Irritation: | 0.049 |
Respiratory Toxicity: | 0.963 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003309 | 0.804 | D0KR9U | 0.229 | ||||
ENC005315 | 0.676 | D0K7LU | 0.223 | ||||
ENC002987 | 0.606 | D03ZZK | 0.221 | ||||
ENC005316 | 0.603 | D02QJH | 0.217 | ||||
ENC003179 | 0.603 | D02JNM | 0.214 | ||||
ENC003159 | 0.603 | D0P0HT | 0.203 | ||||
ENC006041 | 0.566 | D06IIB | 0.203 | ||||
ENC002577 | 0.551 | D0D2VS | 0.202 | ||||
ENC005317 | 0.518 | D0D2TN | 0.201 | ||||
ENC005189 | 0.518 | D0G6AB | 0.200 |